Bicycle Therapeutics director Charles Swanton steps down from board
Bicycle Therapeutics plc disclosed that Charles Swanton left his board seat and advisory role on August 18, 2026, citing personal reasons.
SEC filing
Latest
2 stories
Thursday, August 20
Thursday, July 30
Bicycle Therapeutics reports Q2 2026 pipeline progress, cash into 2030
The company dosed its first pancreatic cancer patient in a nuzefatide pevedotin Phase 2 trial and reported $510.1 million in cash as of June 30, 2026.
SEC filing